Functional and Structural Recovery in Myasthenia Gravis and Rheumatoid Arthritis Using a Biophoton-Emitting Device: A Case Report

Abstract

Background: Myasthenia gravis (MG) is an autoimmune neuromuscular disorder characterized by fluctuating skeletal muscle weakness due to impaired neuromuscular transmission, most often mediated by antibodies against the acetylcholine receptor (AChR). Rheumatoid arthritis (RA) is a chronic systemic autoimmune disease that leads to persistent synovial inflammation, joint deformity, and systemic complications. Standard management for both disorders frequently require long-term immunosuppressive therapy, yet many patients experience incomplete responses or adverse effects. Novel, non-invasive therapeutic strategies are therefore needed. Biophoton therapy, which leverages ultraweak photon emissions to influence cellular metabolism, oxidative stress, and intercellular signaling, has shown promising preliminary results in a variety of chronic neurological and systemic conditions.

Objective: To describe functional, structural, and systemic improvements in two patients with MG one with concomitant RA following the use of Tesla BioHealer devices, which emit biophotons in biologically relevant wavelength ranges.

Methods: This case report documents photographic, functional, and subjective outcomes in two patients after consistent daily use of Tesla BioHealer devices. The first patient, a 64-year-old female with both MG and RA, used one device continuously for 56 days, later increasing to two. The second patient, a 70-year-old female with MG, used two devices daily for four weeks; her spouse, with chronic obstructive pulmonary disease (COPD)/emphysema, also underwent biophoton exposure.

Results: In the first case, baseline photographs revealed pronounced swelling and deformity of the hands consistent with advanced RA and MG-related muscle weakness. After treatment, marked reductions in swelling and deformity were observed, alongside improved joint mobility, enhanced comfort, and greater systemic vitality. In the second case, the patient reported enhanced muscle strength, reduced fatigue, and improved quality of life, while her spouse reported better breathing and reduced reliance on nebulizer therapy. These changes were corroborated by family members and treating clinicians.

Conclusion: These cases provide preliminary evidence that biophoton therapy may improve both structural and functional outcomes in complex autoimmune and neuromuscular conditions. Although limited by anecdotal design and lack of standardized clinical measures, the speed and magnitude of observed benefits support the need for controlled clinical trials to further assess the role of biophoton-generating devices in MG, RA, and related disorders.